Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy

References

• Vogelstein B , KinzlerKW . Cancer genes and the pathways they control . Nat. Med.10 ( 8 ), 789 – 799 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB . The epigenomics of cancer . Cell128 ( 4 ), 683 – 692 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Frigola J , SongJ , StirzakerC , HinshelwoodRA , PeinadoMA , ClarkSJ . Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band . Nat. Genet.38 ( 5 ), 540 – 549 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Baylin SB , HoppenerJW , de BustrosA , SteenberghPH , LipsCJ , NelkinBD . DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas . Cancer Res.46 ( 6 ), 2917 – 2922 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Feinberg AP , VogelsteinB . Hypomethylation distinguishes genes of some human cancers from their normal counterparts . Nature301 ( 5895 ), 89 – 92 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Fraga MF , BallestarE , Villar-GareaAet al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer . Nat. Genet.37 ( 4 ), 391 – 400 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Bolden JE , PeartMJ , JohnstoneRW . Anticancer activities of histone deacetylase inhibitors . Nat. Rev. Drug Discov.5 ( 9 ), 769 – 784 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Xu WS , ParmigianiRB , MarksPA . Histone deacetylase inhibitors: molecular mechanisms of action . Oncogene26 ( 37 ), 5541 – 5552 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Peart MJ , TaintonKM , RuefliAAet al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors . Cancer Res.63 ( 15 ), 4460 – 4471 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Thurn KT , ThomasS , MooreA , MunsterPN . Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer . Future Oncol.7 ( 2 ), 263 – 283 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance . Nat. Rev. Cancer5 ( 4 ), 263 – 274 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hodi FS , O’DaySJ , McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma . N. Engl. J. Med.363 ( 8 ), 711 – 723 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer . N. Engl. J. Med.366 ( 26 ), 2443 – 2454 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , TykodiSS , ChowLQet al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer . N. Engl. J. Med.366 ( 26 ), 2455 – 2465 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nie J , LiuL , LiX , HanW . Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors . Cancer Lett.354 ( 1 ), 12 – 20 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Baylin SB , OhmJE . Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nat. Rev. Cancer6 ( 2 ), 107 – 116 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Brown R , CurryE , MagnaniL , Wilhelm-BenartziCS , BorleyJ . Poised epigenetic states and acquired drug resistance in cancer . Nat. Rev. Cancer14 ( 11 ), 747 – 753 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Yang XJ , SetoE . HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention . Oncogene26 ( 37 ), 5310 – 5318 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dhanak D , JacksonP . Development and classes of epigenetic drugs for cancer . Biochem. Biophys. Res. Commun.455 ( 1–2 ), 58 – 69 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B , ParraM . Histone deacetylases and cancer . Mol. Oncol.6 ( 6 ), 579 – 589 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Glozak MA , SenguptaN , ZhangX , SetoE . Acetylation and deacetylation of non-histone proteins . Gene363 , 15 – 23 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Luo J , LiM , TangY , LaszkowskaM , RoederRG , GuW . Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo . Proc. Natl Acad. Sci. USA101 ( 8 ), 2259 – 2264 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Matsuzaki H , DaitokuH , HattaM , AoyamaH , YoshimochiK , FukamizuA . Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation . Proc. Natl Acad. Sci. USA102 ( 32 ), 11278 – 11283 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Tsai KL , SunYJ , HuangCY , YangJY , HungMC , HsiaoCD . Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification . Nucleic Acids Res.35 ( 20 ), 6984 – 6994 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Maruta H , GreerK , RosenbaumJL . The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules . J. Cell Biol.103 ( 2 ), 571 – 579 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Cohen HY , LavuS , BittermanKJet al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis . Mol. Cell13 ( 5 ), 627 – 638 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Thiagalingam S , ChengKH , LeeHJ , MinevaN , ThiagalingamA , PonteJF . Histone deacetylases: unique players in shaping the epigenetic histone code . Ann. N. Y. Acad. Sci.983 , 84 – 100 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Choudhary C , KumarC , GnadFet al. Lysine acetylation targets protein complexes and co-regulates major cellular functions . Science325 ( 5942 ), 834 – 840 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sadoul K , BoyaultC , PabionM , KhochbinS . Regulation of protein turnover by acetyltransferases and deacetylases . Biochimie90 ( 2 ), 306 – 312 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Yang H , SalzT , Zajac-KayeM , LiaoD , HuangS , QiuY . Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators . FASEB28 ( 10 ), 4265 – 4279 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Muller BM , JanaL , KasajimaAet al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression . BMC Cancer13 , 215 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Weichert W , RoskeA , GekelerVet al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy . Br. J. Cancer98 ( 3 ), 604 – 610 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wada T , KikuchiJ , NishimuraN , ShimizuR , KitamuraT , FurukawaY . Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors . J. Biol. Chem.284 ( 44 ), 30673 – 30683 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Krusche CA , WulfingP , KerstingCet al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis . Breast Cancer Res. Treat.90 ( 1 ), 15 – 23 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Marchion DC , BicakuE , TurnerJG , SchmittML , MorelliDR , MunsterPN . HDAC2 regulates chromatin plasticity and enhances DNA vulnerability . Mol. Cancer Ther.8 ( 4 ), 794 – 801 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Inoue S , MaiA , DyerMJ , CohenGM . Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis . Cancer Res.66 ( 13 ), 6785 – 6792 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Welsbie DS , XuJ , ChenYet al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer . Cancer Res.69 ( 3 ), 958 – 966 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Yokokawa J , CeredaV , RemondoCet al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer . Clin. Cancer Res.14 ( 4 ), 1032 – 1040 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Nishikawa H , SakaguchiS . Regulatory T cells in cancer immunotherapy . Curr. Opin. Immunol.27 , 1 – 7 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bridle BW , ChenL , LemayCGet al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy . Mol. Ther.21 ( 4 ), 887 – 894 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shen L , CiesielskiM , RamakrishnanSet al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models . PLoS ONE7 ( 1 ), e30815 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Tao R , de ZoetenEF , OzkaynakEet al. Deacetylase inhibition promotes the generation and function of regulatory T cells . Nat. Med.13 ( 11 ), 1299 – 1307 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Akimova T , GeG , GolovinaTet al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs . Clin. Immunol.136 ( 3 ), 348 – 363 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Beier UH , WangL , HanR , AkimovaT , LiuY , HancockWW . Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms . Sci. Signal.5 ( 229 ), ra45 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhang H , XiaoY , ZhuZ , LiB , GreeneMI . Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity . Immunol. Cell Biol.90 ( 1 ), 95 – 100 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kim HJ , BaeSC . Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs . Am. J. Trans. Res.3 ( 2 ), 166 – 179 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shi P , ScottMA , GhoshBet al. Synapse microarray identification of small molecules that enhance synaptogenesis . Nat. Commun.2 , 510 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Siow RC , HJF . Redox regulation of microRNAs in health and disease . Free Radic. Biol. Med.64 , 1 – 3 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• West AC , JohnstoneRW . New and emerging HDAC inhibitors for cancer treatment . J. Clin. Invest.124 ( 1 ), 30 – 39 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shabason JE , TofilonPJ , CamphausenK . HDAC inhibitors in cancer care . Oncology (Williston Park)24 ( 2 ), 180 – 185 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Minucci S , PelicciPG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer . Nat. Rev. Cancer6 ( 1 ), 38 – 51 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Glaser KB , StaverMJ , WaringJF , StenderJ , UlrichRG , DavidsenSK . Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines . Mol. Cancer Ther.2 ( 2 ), 151 – 163 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• LaBonte MJ , WilsonPM , FazzoneW , GroshenS , LenzHJ , LadnerRD . DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines . BMC Med. Genomics2 , 67 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Halsall J , GuptaV , O’NeillLP , TurnerBM , NightingaleKP . Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors . PLoS ONE7 ( 3 ), e33453 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Siegel D , HusseinM , BelaniCet al. Vorinostat in solid and hematologic malignancies . J. Hematol. Oncol.2 , 31 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Duvic M , TalpurR , NiXet al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) . Blood109 ( 1 ), 31 – 39 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Modesitt SC , SillM , HoffmanJS , BenderDP . A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study . Gynecol. Oncol.109 ( 2 ), 182 – 186 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Luu TH , MorganRJ , LeongLet al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study . Clin. Cancer Res.14 ( 21 ), 7138 – 7142 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Traynor AM , DubeyS , EickhoffJCet al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study . J. Thorac. Oncol.4 ( 4 ), 522 – 526 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ribas A , WolchokJD . Combining cancer immunotherapy and targeted therapy . Curr. Opin. Immunol.25 ( 2 ), 291 – 296 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lizee G , OverwijkWW , RadvanyiL , GaoJ , SharmaP , HwuP . Harnessing the power of the immune system to target cancer . Annu. Rev. Med.64 , 71 – 90 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS , ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer . N. Engl. J. Med.363 ( 5 ), 411 – 422 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Buonerba C , FerroM , Di LorenzoG . Sipuleucel-T for prostate cancer: the immunotherapy era has commenced . Expert Rev. Anticancer Ther.11 ( 1 ), 25 – 28 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Breitbach CJ , ArulanandamR , De SilvaNet al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans . Cancer Res.73 ( 4 ), 1265 – 1275 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengKW , BellJC . Oncolytic virotherapy . Nat. Biotechnol.30 ( 7 ), 658 – 670 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA , YangJC , RestifoNP . Cancer immunotherapy: moving beyond current vaccines . Nat. Med.10 ( 9 ), 909 – 915 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Klebanoff CA , AcquavellaN , YuZ , RestifoNP . Therapeutic cancer vaccines: are we there yet?Immunol. Rev.239 ( 1 ), 27 – 44 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lai MD , ChenCS , YangCRet al. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine . Cancer Gene Ther.17 ( 3 ), 203 – 211 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lee SY , HuangZ , KangTHet al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination . J. Mol. Med.91 ( 10 ), 1221 – 1231 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bartlett DL , LiuZ , SathaiahMet al. Oncolytic viruses as therapeutic cancer vaccines . Mol. Cancer.12 ( 1 ), 103 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ikeda K , IchikawaT , WakimotoHet al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses . Nat. Med.5 ( 8 ), 881 – 887 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Chang HM , PaulsonM , HolkoMet al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity . Proc. Natl Acad. Sci. USA101 ( 26 ), 9578 – 9583 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Nusinzon I , HorvathCM . Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1 . Proc. Natl Acad. Sci. USA100 ( 25 ), 14742 – 14747 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Nguyen TL , AbdelbaryH , ArguelloMet al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis . Proc. Natl Acad. Sci. USA105 ( 39 ), 14981 – 14986 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Otsuki A , PatelA , KasaiKet al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses . Mol. Ther.16 ( 9 ), 1546 – 1555 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA , YangJC , SherryRMet al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy . Clin. Cancer Res.17 ( 13 ), 4550 – 4557 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bolden JE , ShiW , JankowskiKet al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses . Cell Death Dis.4 , e519 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Murakami T , SatoA , ChunNAet al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma . J. Invest. Dermatol.128 ( 6 ), 1506 – 1516 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lisiero DN , SotoH , EversonRG , LiauLM , PrinsRM . The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells . J. Immunother. Cancer2 , 8 ( 2014 ).
   PubMedGoogle Scholar
• Yao X , AhmadzadehM , LuYCet al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer . Blood119 ( 24 ), 5688 – 5696 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Song DG , YeQ , SantoroS , FangC , BestA , PowellDJJr . Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition . Hum. Gene Ther.24 ( 3 ), 295 – 305 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy . Nat. Rev. Cancer12 ( 4 ), 252 – 264 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dong H , StromeSE , SalomaoDRet al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion . Nat. Med.8 ( 8 ), 793 – 800 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kim K , SkoraAD , LiZet al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells . Proc. Natl Acad. Sci. USA111 ( 32 ), 11774 – 11779 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Juergens RA , WrangleJ , VendettiFPet al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer . Cancer Discov.1 ( 7 ), 598 – 607 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wrangle J , WangW , KochAet al. Alterations of immune response of non-small cell lung cancer with azacytidine . Oncotarget4 ( 11 ), 2067 – 2079 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database: NCT02032810 . https://clinicaltrials.gov/ct2/show/NCT02032810 .
   Google Scholar
• ClinicalTrials Database:NCT01928576 . https://clinicaltrials.gov/ct2/show/NCT01928576 .
   Google Scholar
• ClinicalTrials Database: NCT02395627 . https://clinicaltrials.gov/ct2/show/NCT02395627 .
   Google Scholar
• Sabatier R , FinettiP , MamessierEet al. Prognostic and predictive value of PDL1 expression in breast cancer . Oncotarget6 ( 7 ), 5449 – 5464 ( 2014 ).
   Google Scholar